When screening for colorectal cancer, there are many different test options; however, there has been no consensus on the most appropriate screening method for specific subsets of patients.

Correcting social, economic and healthcare inequalities may have the most significant impact in reducing survival differences in colorectal cancer (CRC) between African Americans and Caucasians, according to a new study.

Mutations in the KRAS oncogene could predict a lack of response to the drug cetuximab in patients with colorectal tumors. For those with the mutations, the drug is likely to be inefficient and possibly harmful, according to researchers at France's Institut National de la Sante et de la Recherche Medicale (INSERM).

A phase III trial of 1,298 colorectal cancer patients has found that a combination of the drugs cetuximab (Erbitux) and irinotecan showed a significant improvement in progression-free survival over just irinotecan alone, according to an international team of researchers.